The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Open accessAbstract
Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study’s primary endpoints were safety and determination of the maximum tolerated dose. Secondary endpoints reported in this interim analysis include the frequency of manufacturing failures and objective radiographic response (ORR) according to modified Response Assessment in Neuro-Oncology criteria. All six patients had progressive, multifocal disease at the time of treatment. In both dose level 1 (1 ×107 cells; n = 3) and dose level 2 (2.5 × 107 cells; n = 3), administration of CART-EGFR-IL13Rα2 cells was associated with early-onset neurotoxicity, most consistent with immune effector cell-associated neurotoxicity syndrome (ICANS), and managed with high-dose dexamethasone and anakinra (anti-IL1R). One patient in dose level 2 experienced a dose-limiting toxicity (grade 3 anorexia, generalized muscle weakness and fatigue). Reductions in enhancement and tumor size at early magnetic resonance imaging timepoints were observed in all six patients; however, none met criteria for ORR. In exploratory endpoint analyses, substantial CAR T cell abundance and cytokine release in the cerebrospinal fluid were detected in all six patients. Taken together, these first-in-human data demonstrate the preliminary safety and bioactivity of CART-EGFR-IL13Rα2 cells in rGBM. An encouraging early efficacy signal was also detected and requires confirmation with additional patients and longer follow-up time. ClinicalTrials.gov identifier: NCT05168423. In an interim analysis of an ongoing phase 1 trial of CAR T cells targeting EGFR and IL13Ra2 in patients with multifocal, recurrent glioblastoma, intrathecal delivery is feasible and well tolerated, with some reductions seen in tumor size.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationRegression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Self-citationO’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Self-citationLong-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168 · cited 1×
“Moreover, patient 1 experienced acute onset headache, nausea and vomiting that may have indicated elevated intracranial pressure, and patients 1, 2, 5 and 6 experienced acute worsening of chronic neurological deficits attributable to tumor location(s): all signs and symptoms potentially consistent…”
BackgroundAhmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T. L., Diouf, O., Wakefield, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0184 · Cited by 850
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Choe, J. H., Watchmaker, P. B., Simic, M. S., Gilbert, R. D., Li, A. W., Krasnow, N. A., Downey, K. M., Yu, W., Carrera, D. A., Celli, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe7378 · Cited by 512
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Cited by
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45
Metadata
- Authors
- Bagley, S. J., Logun, M., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R., Jadlowsky, J. K., Christensen, S., Oner, B. S., Plesa, G., Brennan, A., Gonzalez, V., Chen, F., Sun, Y., Gladney, W., Barrett, D., Nasrallah, M. P., Hwang, W.-T., Ming, G.-L., Song, H., Siegel, D. L., June, C. H., Hexner, E. O., Binder, Z. A., & O’Rourke, D. M.
- Venue
- Nature Medicine
- Published
- 2024-03-13
- Volume
- 30
- Issue
- 5
- Pages
- 1320-1329
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4392741152
- Cited by
- 381
- References
- 28
- FWCI
- 58.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. https://app.cochat.ai/papers/10.1038/s41591-024-02893-z
- The paper
- Bagley, S. J., Logun, M., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R., Jadlowsky, J. K., Christensen, S., Oner, B. S., Plesa, G., Brennan, A., . . . O’Rourke, D. M. (2024). Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nature Medicine. https://doi.org/10.1038/s41591-024-02893-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.